Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: May 17, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

Kenneth C Anderson¹, Melissa Alsina, William Bensinger

¹Dana-Farber/Brigham and Women's Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN

|October 12, 2012

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CART-immune-related adverse events after BCMA CAR-T therapy.

Molecular therapy. Oncology·2026

Same author

Brexucabtagene Autoleucel in the Outpatient Setting: A Single-Institution Experience.

Transplantation and cellular therapy·2026

Same author

Non-ICANS Neurologic Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Ciltacabtagene Autoleucel: Clinical Presentation and Management in CARTITUDE Studies.

Clinical lymphoma, myeloma & leukemia·2026

Same author

Is Pseudo-progression post-CAR T therapy real?

Clinical hematology international·2026

Same author

Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active Surveillance.

Cancer medicine·2026

Same author

Rab5 improves CAR T cell efficacy via reducing fratricide and maintaining surface CAR levels.

The Journal of experimental medicine·2026

New NCCN Guidelines offer updated management strategies for Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma. Key changes include novel therapies, revised response criteria, and peripheral neuropathy management.

Area of Science:

Hematology
Oncology
Clinical Guidelines

Background:

Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma requires updated management protocols.
The NCCN Guidelines provide essential updates for clinicians.

Purpose of the Study:

To highlight key changes in the NCCN Guidelines for Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma.
To inform clinicians about novel therapeutic options and updated criteria.

Main Methods:

Review of recent clinical advancements and consensus recommendations.
Inclusion of data from the sixth international workshop on Waldenström's Macroglobulinemia.

Main Results:

Novel therapeutic regimens are now recommended for primary and salvage therapy.

More Related Videos

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Related Experiment Videos

Last Updated: May 17, 2026

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Updated response categories and criteria are incorporated.

A dedicated section on peripheral neuropathy management is included.

Conclusions:

The updated NCCN Guidelines provide a comprehensive framework for managing Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma.
These insights emphasize the integration of novel agents and refined assessment methods.